What are the next steps for a patient who develops a fever after a pembrolizumab (pembrolizumab) infusion and is currently taking Tylenol (acetaminophen)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Fever After First Pembrolizumab Infusion

This fever 3 hours post-infusion is most likely a Grade 1-2 infusion reaction, and you should continue symptomatic treatment with acetaminophen, monitor vital signs closely for the next 1-2 hours, and watch for any progression to more severe symptoms that would indicate a Grade 3-4 reaction requiring aggressive intervention. 1, 2

Immediate Assessment and Classification

The clinical scenario describes a Grade 1-2 infusion reaction, characterized by:

  • Pyrexia (101.3°F) occurring 4 hours after infusion start 1
  • Pembrolizumab infusion reactions occur in approximately 3% of patients, with pyrexia and chills being the primary symptoms 1
  • The patient has already received appropriate initial management with acetaminophen 1000mg 2

This fever pattern is consistent with a typical infusion reaction rather than infection, given the temporal relationship (within hours of infusion) and the known side effect profile of pembrolizumab. 1, 2

Current Management Steps

Continue Symptomatic Treatment

  • The acetaminophen 1000mg already administered is appropriate first-line therapy 2
  • Consider adding an antihistamine (diphenhydramine 25-50 mg IV or oral) if not already given 2, 3
  • Monitor temperature every 30-60 minutes until fever resolves 2

Vital Sign Monitoring

  • Check vital signs every 15 minutes for the next 1-2 hours, including blood pressure, heart rate, respiratory rate, and oxygen saturation 2, 3
  • Watch specifically for signs of progression to Grade 3-4 reactions, including bronchospasm, severe respiratory compromise, severe hypotension, or angioedema 1, 4

Observation Period

  • Observe the patient for at least 1-2 hours after symptom onset, as infusion reactions can progress 2, 3
  • Be aware that delayed reactions can occur up to 24 hours post-infusion 2

Red Flags Requiring Escalation

Immediately escalate care if any of the following develop:

  • Bronchospasm, wheezing, or severe dyspnea 1, 4
  • Severe hypotension or hemodynamic instability 1, 4
  • Angioedema, facial swelling, or severe urticaria 1, 4
  • Chest pain, back pain, or feeling like passing out 4
  • Any Grade 3-4 reaction requires permanent discontinuation of pembrolizumab 1

Prevention for Next Infusion

For the second pembrolizumab infusion, implement the following premedication protocol:

  • Administer acetaminophen 1000 mg orally 30-60 minutes before infusion 1, 2
  • Give antihistamine (diphenhydramine 25-50 mg or equivalent) prior to infusion 1, 2
  • Consider starting the infusion at a slower rate and gradually increasing if tolerated 2, 3

Patient Education

Educate the patient about:

  • Delayed reactions can occur up to 24 hours after infusion 2
  • Report immediately: difficulty breathing, chest tightness, severe rash, dizziness, or worsening fever 4
  • Continue monitoring temperature at home for 24 hours 2

Important Caveats

Do not confuse this infusion reaction with immune-related adverse events (irAEs):

  • Fever occurring weeks to months after pembrolizumab may represent serious irAEs like pneumonitis, colitis, or hemophagocytic lymphohistiocytosis, which require different management 5, 6, 7
  • The timing (within hours of infusion) strongly suggests infusion reaction rather than irAE 1, 2

This is NOT an indication to permanently discontinue pembrolizumab unless symptoms progress to Grade 3-4 severity. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.